Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous bone-marrow-derived stem cells for motor neuron disease
NCT03067857Phase 2Unknown
- Sponsor
- Stem Cells Arabia
- Start
- Sep 2016
- Primary completion
- Jan 2019
- Modality
- Stem Cell Therapies
01
Overview
Phase 2, open-label, single-arm trial of autologous bone marrow-derived stem cells in motor neuron disease (MND), amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS) and 2 more, sponsored by Stem Cells Arabia. Primary endpoint: Functional Rating Scale at 6 months. Status: unknown.
02
Drugs
autologous bone marrow-derived stem cells
03
Conditions
motor neuron disease (MND)amyotrophic lateral sclerosis (ALS)primary lateral sclerosis (PLS)progressive muscular atrophy (PMA)progressive bulbar palsy (PBP)
Beyond the preview
Go deeper on NCT03067857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03067857.